Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab as Second-line Treatment in MSS Type Metastatic Colorectal Cancer Based on RAS Gene Status
Conditions
Interventions
AK104 and cetuximab or bevacizumab and FOLFIRI
Locations
2
China
the Second Affiliated Hospital of Medical College of Zhejiang University
Hangzhou, Zhejiang, China
the Second Affiliated Hospital of Medical College of Zhejiang University
Hangzhou, China
Start Date
January 3, 2024
Primary Completion Date
January 3, 2026
Completion Date
January 3, 2027
Last Updated
November 28, 2025
NCT07256522
NCT04592640
NCT04854278
NCT06244537
NCT05583006
NCT03901235
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions